CJC-1295 with DAC: research

CJC-1295 with DAC dosage

Typical reported dose: 1–2 mg total per week

• One trial injection: 30 mcg/kg: 30 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 60 mcg/kg: 60 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 125 mcg/kg: 125 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 250 mcg/kg: 250 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• 30 mcg/kg every 14 days, two doses: 30 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)
• 60 mcg/kg every 14 days, two doses: 60 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)

Highest studied: Published weekly arm: 30 mcg/kg on days 0, 7 and 14; body weight is needed for an mg comparison..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

CJC-1295 with DAC side effects and risks

Reported side effects

• Injection-site irritation, redness, pain or itching: About 70% active in the single dose trial; all 20 active in the repeat dose trial; placebo redness 3/4 in repeat dosing., mild. Check persistent or spreading redness; fever, pus or severe pain needs urgent assessment. (source)
• Headache: Single dose: 63% active versus 14% placebo. Repeat dosing: 20–80% across active groups versus 50% placebo., moderate. Severe headache or vision change needs urgent care. (source)
• Diarrhea: 43% active versus 0% placebo; 45% at 125 and 100% at 250 mcg/kg in the published report., moderate (source)
• Flushing, warmth or transient low blood pressure: Single dose: 30% active, 0% placebo. Repeat dosing: flushing 40–100%, depending on dose., moderate. Fainting, chest pain or persistent fast heart rate needs urgent assessment. (source)
• Local hives: Almost 30% of active recipients in the single dose trial., moderate. Widespread hives, throat swelling or breathing trouble is an emergency. (source)
• Nausea or abdominal pain: 20% reported in the trial paper; placebo 0%. Exact pooled denominator was not clear., moderate (source)
• Faster heart rate: Dose related in the 12 man pulse study; counts and rates unavailable., moderate (source)
• High blood sugar, swelling or joint pain: Seen with related tesamorelin; CJC rates remain unknown. Short DAC trials found no consistent blood sugar change., moderate (source)
• Serious allergic or immune reactions: FDA identifies immunogenicity concerns; frequency with repeated exposure is unknown., serious (source)
• Fatal heart attack during a trial: One death after dose 11 in the terminated HIV trial. Causation and a reliable incidence rate are unresolved., serious (source)

Stop and get help if

• Trouble breathing, throat or face swelling, widespread hives, or collapse: Stop using CJC-1295 and call emergency services now.
• Chest pain, fainting, severe breathlessness, or a sustained racing heart: Stop exposure and seek emergency care now.
• Severe headache with vision change, vomiting, or new weakness: Get emergency care now; do not assume this is normal flushing.
• Rapid swelling or weight gain with shortness of breath: Seek urgent care now for possible fluid overload or heart problems.
• Hot spreading injection-site redness, severe pain, pus, or fever: Stop injections and get urgent same-day care; fever or rapidly worsening illness needs emergency care.
• Confusion, vomiting, marked thirst or urination, or low sugar that does not improve: Check blood sugar if available and seek urgent care; severe confusion or unconsciousness needs emergency services.

Who should avoid it

• pregnant: CJC pregnancy safety is unknown. Stop use during pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; avoid exposing a nursing infant.
• tryingToConceive: Fertility and early-pregnancy effects are unknown. This is a precautionary screen.
• under18: FDA found no safety data in children. Growth hormone stimulation can affect growth.
• activeCancer: Growth hormone can support cell growth. Avoid CJC with active cancer, following related-drug precautions.
• cancerHistory: A prior cancer needs individual review; long-term recurrence risk with CJC is unknown.
• other: Excess growth hormone makes CJC unsuitable; pituitary disease needs specialist review.
• other: A serious allergy to CJC or its vial ingredients means avoiding further use.
• diabetes: Growth hormone can raise blood sugar. Diabetes was excluded from the HIV study; direct safety data are lacking.
• diabeticRetinopathy: Related tesamorelin guidance warns about worsening diabetic eye disease; CJC-specific risk is unknown.
• heartCondition: Heart-rate and blood-pressure changes matter with heart disease; longer-term cardiac safety is unknown.
• uncontrolledBloodPressure: Blood-pressure instability and GH-related fluid retention warrant review before further exposure.
• sleepApnea: Sleep apnea raises baseline cardiometabolic risk; new snoring or breathing pauses need assessment.
• kidneyDisease: No kidney dosing study was found. Kidney disease can also cause swelling and change hormone tests.
• liverDisease: No liver dosing study was found; liver disease can distort IGF-1 blood tests.
• surgeryPlanned: Tell the anesthesia team about peptide and other hormone use; no perioperative CJC safety study was found.
• testedAthlete: WADA prohibits GHRH analogues at all times, including CJC-1295.

Interactions

• Insulin: A related drug, tesamorelin, can raise blood sugar. CJC effects on insulin needs are unknown; review readings when exposure starts or stops.
• Sulfonylureas: CJC interactions are unknown. These medicines can cause severe low blood sugar; review readings with your clinician when CJC starts or stops.
• Other GH, GHRH or ghrelin-pathway drugs: Effects may add, raising IGF-1 or glucose and fluid-retention concerns. No CJC/ipamorelin combination trial was found.
• Glucocorticoid replacement: Tesamorelin's label warns growth hormone can lower cortisol and change steroid replacement needs. This is untested with CJC.
• Medicines affected by liver CYP enzymes: Tesamorelin's label warns growth hormone may change drug breakdown. CJC interactions and medication adjustments are unknown.
• Anticoagulants: Blood thinners increase bleeding and bruising from needle punctures. A direct CJC drug interaction has not been demonstrated.

Product quality risks

• DAC and no-DAC names are confused. FDA considers them different active moieties with different safety and exposure profiles.
• FDA found missing impurity, aggregate and endotoxin data in reviewed certificates. A high purity percentage alone cannot show injection safety.
• A 2010 seized sample contained a 29-amino-acid peptide consistent with the short form sold as CJC-1295; it was not proof of DAC identity.
• A 2019 seizure study identified glycine-added modified GRF and other secretagogues. Seized material is not a representative market survey.
• Regulators warn unapproved peptide vials may have too much, too little or no stated ingredient, particles, microbes or endotoxin.

How CJC-1295 with DAC works

It mimics the signal that tells the pituitary to release growth hormone. The DAC tag attaches to blood albumin, prolonging exposure. GH then raises IGF-1. In one small study, normal bursts continued while the baseline GH level rose.

• GHRH receptor: Stimulates pituitary growth hormone release.
• Serum albumin: DAC forms a long-lasting attachment that prolongs exposure.
• GH–IGF-1 pathway: Raises circulating IGF-1; a hormone change does not establish a health benefit.

Half-life: 5.8–8.1 days after a single dose; repeat-dose estimates 5.4–9.2 days.